Target intelligence / Profile preview

Retinoic acid receptor alpha, beta, gamma (RAR-α, RAR-β, RAR-γ)

Target
RAR-α, RAR-β, RAR-γ
Molecular classification
Nuclear receptor, Transcription factor, Ligand-activated transcription regulator
01

Overview

Retinoic acid receptor alpha, beta, and gamma are members of the nuclear receptor superfamily, encoded by distinct genes (RARA, RARB, and RARG). These receptors are activated by retinoic acid, a metabolite of vitamin A, and regulate gene transcription involved in development, differentiation, cell proliferation, and apoptosis. Upon ligand binding, RARs form heterodimers with retinoid X receptors (RXRs), recruit coactivators, and drive expression of genes with retinoic acid response elements (RAREs). Expression and function of each RAR subtype can be tissue-specific, and they play both shared and unique roles in embryonic and adult physiology, disease processes, and as drug targets for retinoids (especially in cancer and dermatology). Resistance and toxicity are clinical challenges in retinoid-based therapies.

Other names
RAR-alphaRAR-αNR1B1RAR-betaRAR-βNR1B2RAR-gammaRAR-γNR1B3Retinoic acid receptor (RAR)Nuclear retinoic acid receptor
02

Mechanism of action

Ligand binding to RAR causes dissociation of corepressors (NCOR, SMRT), recruitment of coactivators, and transcriptional activation of target genes. Drives gene expression involved in cell cycle regulation, differentiation, and apoptosis

03

Biological functions

Regulation of gene expressionCell proliferationCell differentiation and developmentApoptosisOrganogenesis, embryogenesisHematopoietic stem cell maintenance
04

Disease associations

Cancer (especially acute promyelocytic leukemia; implicated in solid tumors as well)Dermatological disorders (e.g., psoriasis, acne)Developmental disordersMetabolic diseases
05

Safety considerations

Teratogenicity (developmental abnormalities in the fetus if used in pregnancy)Hypervitaminosis A-like toxicityDermatologic irritation, mucocutaneous effects (especially topical application)Potential for resistance mechanisms in cancer
06

Interacting drugs

All-trans retinoic acid (ATRA)

4 more in the full profile.

07

Biomarkers

RARA fusion gene (e.g., PML-RARA in acute promyelocytic leukemia; diagnostic and therapeutic response marker)Expression levels of RAR subtypes in tissues for prediction of retinoid efficacyResponse element presence (RAREs in gene promoters)

Beyond the preview

Go deeper on Retinoic acid receptor alpha, beta, gamma (RAR-α, RAR-β, RAR-γ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Retinoic acid receptor alpha, beta, gamma (RAR-α, RAR-β, RAR-γ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call